ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1031
-0,53%
Bitcoin
66.847,89
2,47%
Brent Oil
83,725
0,62%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Cytrx Corp. (MM) (CYTR)

  7. Cytrx Corp. (MM) (CYTR) Notícias

CYTR

Cytrx (CYTR)

Cytrx Corp. (MM)
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CYTR
DataHoraFonteTítuloCódigoCompanhia
19/12/201908:05Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CYTRCytrx Corp. (MM)
17/12/201916:23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CYTRCytrx Corp. (MM)
14/11/201908:15Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CYTRCytrx Corp. (MM)
01/08/201917:14Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:CYTRCytrx Corp. (MM)
26/06/201907:16Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:CYTRCytrx Corp. (MM)
24/06/201910:38Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...NASDAQ:CYTRCytrx Corp. (MM)
06/06/201917:35Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CYTRCytrx Corp. (MM)
31/05/201910:00PR Newswire (US)CytRx Corporation to Commence Trading on OTCQB Venture MarketNASDAQ:CYTRCytrx Corp. (MM)
15/05/201910:00PR Newswire (US)CytRx Corporation Reports First Quarter 2019 Financial ResultsNASDAQ:CYTRCytrx Corp. (MM)
08/05/201910:00PR Newswire (US)CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain CancerNASDAQ:CYTRCytrx Corp. (MM)
02/05/201910:00PR Newswire (US)CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/SNASDAQ:CYTRCytrx Corp. (MM)
29/04/201910:00PR Newswire (US)CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted ...NASDAQ:CYTRCytrx Corp. (MM)
29/03/201910:00PR Newswire (US)CytRx Corporation Reports 2018 Financial ResultsNASDAQ:CYTRCytrx Corp. (MM)
29/03/201907:22Edgar (US Regulatory)Annual Report (10-k)NASDAQ:CYTRCytrx Corp. (MM)
12/03/201910:00PR Newswire (US)CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To ...NASDAQ:CYTRCytrx Corp. (MM)
13/02/201912:00PR Newswire (US)CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR™ Technology Targeting Delivery Directly to the TumorNASDAQ:CYTRCytrx Corp. (MM)
11/02/201912:00PR Newswire (US)CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidate...NASDAQ:CYTRCytrx Corp. (MM)
06/02/201912:00PR Newswire (US)CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (...NASDAQ:CYTRCytrx Corp. (MM)
14/01/201912:00PR Newswire (US)CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical TrialNASDAQ:CYTRCytrx Corp. (MM)
04/01/201917:48Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CYTRCytrx Corp. (MM)
21/12/201812:00PR Newswire (US)CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR™ Drug Candidat...NASDAQ:CYTRCytrx Corp. (MM)
28/11/201812:00PR Newswire (US)CytRx Corporation to Present at the 11th Annual LD Micro Main EventNASDAQ:CYTRCytrx Corp. (MM)
08/11/201812:00PR Newswire (US)CytRx Corporation Highlights NantCell Inc's Clinical Data with Aldoxorubicin Presented at the Society for Immunotherapy of Ca...NASDAQ:CYTRCytrx Corp. (MM)
02/11/201810:00PR Newswire (US)CytRx Corporation Reports Third Quarter 2018 Financial ResultsNASDAQ:CYTRCytrx Corp. (MM)
31/10/201810:00PR Newswire (US)Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies PipelineNASDAQ:CYTRCytrx Corp. (MM)
29/10/201810:00PR Newswire (US)CytRx to Hold Third Quarter 2018 Financial Results Conference Call and Webcast on Friday, November 2, 2018NASDAQ:CYTRCytrx Corp. (MM)
25/09/201810:00PR Newswire (US)CytRx Corporation to Present at the 2018 MicroCap ConferenceNASDAQ:CYTRCytrx Corp. (MM)
13/09/201810:00PR Newswire (US)CytRx Corporation Announces Receipt of Milestone Payment from Orphazyme A/SNASDAQ:CYTRCytrx Corp. (MM)
27/08/201810:00PR Newswire (US)CytRx Corporation to Present at the H.C. Wainwright & Co. 20th Annual Global Investment Conference in New York City September...NASDAQ:CYTRCytrx Corp. (MM)
06/08/201809:30PR Newswire (US)CytRx Corporation Reports Second Quarter 2018 Financial ResultsNASDAQ:CYTRCytrx Corp. (MM)
 Apresentando as notícias mais relevantes sobre:NASDAQ:CYTR

Seu Histórico Recente

USOTC
RFHTS
RSE Archive (GM)
COIN
INBOXGBP
Inbox Token
COIN
OWNEUR
LSE
0RA5
Electro Power Systems
EU
H951T
H951T
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados